Kyme Pierre 4

What Happened
Kyme Pierre, Chief Business Officer of Armata Pharmaceuticals (ARMP), received an award of derivative securities on March 9, 2026: stock options covering 183,142 shares at an exercise/acquisition price of $0.00 reported on the Form 4 (transaction coded as an award/grant). The filing reports $0 cash paid for the grant; this is a compensation award (not a cash purchase or sale) that requires future vesting and potential exercise to convert to common shares.

Key Details

• Transaction date: 2026-03-09; filing date: 2026-03-11 (filed within the normal 2-business-day window).
• Security: derivative award labeled as stock options covering 183,142 shares; reported price $0.00.
• Shares owned after transaction: not specified in the filing.
• Vesting (footnote): 25% of the options vest on March 9 of each year 2027, 2028, 2029 and 2030, subject to continuous service.
• No 10b5-1 plan, tax-withholding, or immediate sale reported in this filing.

Context
This is a standard equity-compensation grant to an executive — options typically align management incentives but do not represent immediate ownership of stock until vesting and exercise occur. Because the award vests over four years, there is a service condition before shares can be realized; such grants are common and not, by themselves, a direct market-buy signal.